CD274 and hepatocellular carcinoma: Xiao et al. proved that the naturally-modified molecule EZH2 can lower PD-L1 expression by directly upregulating the levels of the promoter H3K27me3 in HCC, providing a promising strategy for HCC immunotherapy [30].